
    <table class="diff" id="difflib_chg_to535__top"
           cellspacing="0" cellpadding="0" rules="groups" >
        <colgroup></colgroup> <colgroup></colgroup> <colgroup></colgroup>
        <colgroup></colgroup> <colgroup></colgroup> <colgroup></colgroup>
        
        <tbody>
            <tr><td class="diff_next" id="difflib_chg_to535__0"></td><td class="diff_header" id="from535_243">243</td><td >Certain progestins can be used at very high doses to [[appetite stimulant|increase appetite]] in conditions like [[cachexia]], [[anorexia (symptom)|anorexia]], and [[wasting syndrome]]s. In general, they are used in combination with certain other steroid medications such as [[dexamethasone]]. Their effects take several weeks to become apparent, but are relatively long-lived when compared to those of [[corticosteroid]]s. Furthermore, they are recognized as being the only medications to increase [[lean body mass]]. [[Megestrol acetate]] is the lead drug of this class for the management of cachexia, and [[medroxyprogesterone acetate]] is also used.&lt;ref name="pmid11332139"&gt;{{cite journal |vauthors=Maltoni M, Nanni O, Scarpi E, Rossi D, Serra P, Amadori D | title = High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials | journal = Ann. Oncol. | volume = 12 | issue = 3 | pages = 289–300 |date=March 2001 | pmid = 11332139 | doi = 10.1023/a:1011156811739 | doi-access = free}}&lt;/ref&gt;&lt;ref name="pmid12868546"&gt;{{cite journal |vauthors=Lelli G, Montanari M, Gilli G, Scapoli D, Antonietti C, Scapoli D | title = Treatment of the cancer anorexia-cachexia syndrome: a critical reappraisal | journal = J Chemother | volume = 15 | issue = 3 | pages = 220–5 |date=June 2003 | pmid = 12868546 | doi = 10.1179/joc.2003.15.3.220 | s2cid = 29442148}}&lt;/ref&gt; The [[mechanism of action]] of the appetite-related effects of these two medications is unknown and may not be related to their progestogenic activity. Very high doses of other progestogens, like [[cyproterone acetate]], have minimal or no influence on appetite and weight.</td><td class="diff_next"></td><td class="diff_header" id="to535_243">243</td><td >Certain progestins can be used at very high doses to [[appetite stimulant|increase appetite]] in conditions like [[cachexia]], [[anorexia (symptom)|anorexia]], and [[wasting syndrome]]s. In general, they are used in combination with certain other steroid medications such as [[dexamethasone]]. Their effects take several weeks to become apparent, but are relatively long-lived when compared to those of [[corticosteroid]]s. Furthermore, they are recognized as being the only medications to increase [[lean body mass]]. [[Megestrol acetate]] is the lead drug of this class for the management of cachexia, and [[medroxyprogesterone acetate]] is also used.&lt;ref name="pmid11332139"&gt;{{cite journal |vauthors=Maltoni M, Nanni O, Scarpi E, Rossi D, Serra P, Amadori D | title = High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials | journal = Ann. Oncol. | volume = 12 | issue = 3 | pages = 289–300 |date=March 2001 | pmid = 11332139 | doi = 10.1023/a:1011156811739 | doi-access = free}}&lt;/ref&gt;&lt;ref name="pmid12868546"&gt;{{cite journal |vauthors=Lelli G, Montanari M, Gilli G, Scapoli D, Antonietti C, Scapoli D | title = Treatment of the cancer anorexia-cachexia syndrome: a critical reappraisal | journal = J Chemother | volume = 15 | issue = 3 | pages = 220–5 |date=June 2003 | pmid = 12868546 | doi = 10.1179/joc.2003.15.3.220 | s2cid = 29442148}}&lt;/ref&gt; The [[mechanism of action]] of the appetite-related effects of these two medications is unknown and may not be related to their progestogenic activity. Very high doses of other progestogens, like [[cyproterone acetate]], have minimal or no influence on appetite and weight.</td></tr>
            <tr><td class="diff_next"></td><td class="diff_header" id="from535_244">244</td><td ></td><td class="diff_next"></td><td class="diff_header" id="to535_244">244</td><td ></td></tr>
            <tr><td class="diff_next"></td><td class="diff_header" id="from535_245">245</td><td >==Contraindications==</td><td class="diff_next"></td><td class="diff_header" id="to535_245">245</td><td >==Contraindications==</td></tr>
            <tr><td class="diff_next"><a href="#difflib_chg_to535__top">t</a></td><td class="diff_header" id="from535_246">246</td><td >[[Contraindication]]s of progestogens may include [[breast cancer]] and a history of [[venous thromboembolism]] among others.&lt;ref&gt;{{cite web|url=https://www.stoptheclot.org/about-clots/webinar_contra/birth_control_clots/|title=IS IT TRUE THAT BIRTH CONTROL PILLS CAUSE BLOOD CLOTS?|work=[[National Blood Clot Alliance]]|access-date=<span class="diff_chg">{{date|</span>2019<span class="diff_sub">-04-15}}</span>|url-status=live|archive-url=https://web.archive.org/web/20190415024630/https://www.stoptheclot.org/about-clots/webinar_contra/birth_control_clots/|archive-date=<span class="diff_chg">{{date|</span>2019<span class="diff_sub">-04-15}}</span>}}&lt;/ref&gt;{{citation needed|date=July 2018}}</td><td class="diff_next"><a href="#difflib_chg_to535__top">t</a></td><td class="diff_header" id="to535_246">246</td><td >[[Contraindication]]s of progestogens may include [[breast cancer]] and a history of [[venous thromboembolism]] among others.&lt;ref&gt;{{cite web|url=https://www.stoptheclot.org/about-clots/webinar_contra/birth_control_clots/|title=IS IT TRUE THAT BIRTH CONTROL PILLS CAUSE BLOOD CLOTS?|work=[[National Blood Clot Alliance]]|access-date=<span class="diff_chg">15 April </span>2019|url-status=live|archive-url=https://web.archive.org/web/20190415024630/https://www.stoptheclot.org/about-clots/webinar_contra/birth_control_clots/|archive-date=<span class="diff_chg">15 April </span>2019}}&lt;/ref&gt;{{citation needed|date=July 2018}}</td></tr>
            <tr><td class="diff_next"></td><td class="diff_header" id="from535_247">247</td><td ></td><td class="diff_next"></td><td class="diff_header" id="to535_247">247</td><td ></td></tr>
            <tr><td class="diff_next"></td><td class="diff_header" id="from535_248">248</td><td >==Side effects==</td><td class="diff_next"></td><td class="diff_header" id="to535_248">248</td><td >==Side effects==</td></tr>
            <tr><td class="diff_next"></td><td class="diff_header" id="from535_249">249</td><td >Progestogens have relatively few [[side effect]]s at typical dosages.&lt;ref name="pmid2215269t"&gt;{{cite journal | vauthors = Lauritzen C | title = Clinical use of oestrogens and progestogens | journal = Maturitas | volume = 12 | issue = 3 | pages = 199–214 | date = September 1990 | pmid = 2215269 | doi = 10.1016/0378-5122(90)90004-P}}&lt;/ref&gt; Side effects of progestogens may include [[tiredness]], [[dysphoria]], [[depression (mood)|depression]], [[mood (psychology)|mood]] changes, [[irregular menstruation|menstrual irregularities]], [[hypomenorrhea]], [[edema]], [[vaginal dryness]], [[vaginal atrophy]], [[headache]]s, [[nausea]], [[breast tenderness]], decreased [[libido]].&lt;ref name="pmid16112947t" /&gt;&lt;ref name="pmid15358281" /&gt;&lt;ref name="pmid2215269t" /&gt; Progestins with androgenic activity, namely 19-nortestosterone derivatives, can also cause [[acne]], [[hirsutism]], [[seborrhea]], [[voice deepening]], changes in [[liver protein production]] (e.g., decreased [[HDL cholesterol]], [[sex hormone-binding globulin]]), increased [[appetite]], and [[weight gain]], among others.&lt;ref name="pmid16112947t" /&gt;&lt;ref name="pmid2215269t" /&gt; Other side effects of progestogens may include an increased risk of [[breast cancer]], [[cardiovascular disease]], and [[blood clot]]s, among others.&lt;ref name="pmid15358281" /&gt; Some of the side effects of progestogens are due not to their progestogenic activity but rather due to [[off-target activity|off-target activities]] (e.g., [[androgen]]ic activity, [[glucocorticoid]] activity, [[antimineralocorticoid]] activity).&lt;ref name="pmid16112947t" /&gt;&lt;ref name="pmid21414337" /&gt; At high doses, due to their [[antigonadotropic]] effects, progestogens can cause [[hypogonadism|low sex hormone levels]] and associated side effects like diminished [[secondary sexual characteristics]], [[sexual dysfunction]] (e.g., reduced [[sex drive]] and [[erectile dysfunction]]), reversible [[infertility]], reduced [[bone mineral density]], and an increased risk of [[bone fracture]]s, both in men and in [[premenopause|premenopausal]] women.&lt;ref name="pmid20459370" /&gt;</td><td class="diff_next"></td><td class="diff_header" id="to535_249">249</td><td >Progestogens have relatively few [[side effect]]s at typical dosages.&lt;ref name="pmid2215269t"&gt;{{cite journal | vauthors = Lauritzen C | title = Clinical use of oestrogens and progestogens | journal = Maturitas | volume = 12 | issue = 3 | pages = 199–214 | date = September 1990 | pmid = 2215269 | doi = 10.1016/0378-5122(90)90004-P}}&lt;/ref&gt; Side effects of progestogens may include [[tiredness]], [[dysphoria]], [[depression (mood)|depression]], [[mood (psychology)|mood]] changes, [[irregular menstruation|menstrual irregularities]], [[hypomenorrhea]], [[edema]], [[vaginal dryness]], [[vaginal atrophy]], [[headache]]s, [[nausea]], [[breast tenderness]], decreased [[libido]].&lt;ref name="pmid16112947t" /&gt;&lt;ref name="pmid15358281" /&gt;&lt;ref name="pmid2215269t" /&gt; Progestins with androgenic activity, namely 19-nortestosterone derivatives, can also cause [[acne]], [[hirsutism]], [[seborrhea]], [[voice deepening]], changes in [[liver protein production]] (e.g., decreased [[HDL cholesterol]], [[sex hormone-binding globulin]]), increased [[appetite]], and [[weight gain]], among others.&lt;ref name="pmid16112947t" /&gt;&lt;ref name="pmid2215269t" /&gt; Other side effects of progestogens may include an increased risk of [[breast cancer]], [[cardiovascular disease]], and [[blood clot]]s, among others.&lt;ref name="pmid15358281" /&gt; Some of the side effects of progestogens are due not to their progestogenic activity but rather due to [[off-target activity|off-target activities]] (e.g., [[androgen]]ic activity, [[glucocorticoid]] activity, [[antimineralocorticoid]] activity).&lt;ref name="pmid16112947t" /&gt;&lt;ref name="pmid21414337" /&gt; At high doses, due to their [[antigonadotropic]] effects, progestogens can cause [[hypogonadism|low sex hormone levels]] and associated side effects like diminished [[secondary sexual characteristics]], [[sexual dysfunction]] (e.g., reduced [[sex drive]] and [[erectile dysfunction]]), reversible [[infertility]], reduced [[bone mineral density]], and an increased risk of [[bone fracture]]s, both in men and in [[premenopause|premenopausal]] women.&lt;ref name="pmid20459370" /&gt;</td></tr>
        </tbody>
    </table>